Identity
Dermorphin is a potent opioid peptide originally isolated from amphibian skin.
Source-specific finding, not full clinical sign-off.
Peptide library
Dermorphin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Potent animal analgesia establishes opioid activity, not a safe therapeutic margin for people. A pain-response experiment cannot exclude respiratory or dependence risks or justify a consumer pain protocol.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Animal and isolated-tissue pharmacology.
What the sources found
Analgesic activity in animals does not establish a safe human pain-treatment regimen.
Regulatory scope
Current authorization must be checked for the exact product, indication and jurisdiction.
What remains unknown
Limited selected-source check, not an exhaustive review. Full methods, complete safety, exact formulation/route pharmacokinetics, stability and current jurisdictional authorization remain outstanding.
How it works
Dermorphin is a potent opioid peptide originally isolated from amphibian skin.
Read the source-specific findings; biological activity is not equivalent to a clinical treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- Animal experiments reported tolerance, withdrawal and catalepsy; human safety is not established by this source.
Source-specific finding, not full clinical sign-off.
Contraindications
- Full clinical contraindication and interaction assessment remains outstanding.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Analgesic activity in animals does not establish a safe human pain-treatment regimen.
Source-specific finding, not full clinical sign-off.
Adverseeffects
Animal experiments reported tolerance, withdrawal and catalepsy; human safety is not established by this source.
Source-specific finding, not full clinical sign-off.
References
Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin. 1981.
PMID: 7195758
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.